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Generation or enhancement of immune responses through en-
gagement of costimulatory receptors such as CD40 ligation is
an essential component of antitumor immunity and could be
exploited in glioma immunotherapy. Nevertheless, the impor-
tance of adequate immune stimulation is somewhat overshad-
owed by the current rush towards blocking immune inhibition
using checkpoint-blockade antibodies. Therefore, the current
study by Chonan et al1 in which CD40/CD40L expression and
manipulation are revisited in glioma is a useful reminder of
the stimulatory component of antiglioma immunity.
The best understood role of CD40/CD40L is in immune cell
interactions. The CD40 glycoprotein and its ligand CD40L
(CD154) are members of the tumor necrosis factor (TNF) and
TNF receptor superfamily. CD40 is expressed on dendritic
cells, B cells, and macrophages; upon ligation with CD40L ex-
pressed by activated CD4T cells, the antigen-presenting func-
tion of these cell types is enhanced, inflammatory mediators
are released, and B cells differentiate towards plasma cells or
memory cells.2 Moreover, these immunostimulatory effects
can be recapitulated using agonistic anti-CD40 antibodies.
However, exploiting this pathway is complex because of differ-
ent downstream consequences after CD40 ligation according
to cell type and context. In fact, expression of CD40 occurs
not only on the key immune cells listed above but also on non-
immune cells including endothelial cells, epithelial cells, and
platelets.2 Similarly, CD40L has a wide expression pattern
with expression noted by platelets, endothelial cells, fibroblasts,
and muscle cells, particularly in the context of inflammation.3
In the case of malignancy, expression and function of CD40
and CD40L on the tumor cell enlarge the potential interactions
and consequences. Indeed, tumor cell expression of CD40 is
quite frequent, with most hematological malignancies express-
ing CD40, as well as expression being reported in melanoma,
multiple carcinomas (reviewed by Vonderheide4) and a few
studies concerning glioma.1,5,6 Chonan et al1 made the intriguing
observations that CD40 is more highly expressed by grade III gli-
omas than grade IV glioblastoma, that there is also coexpression
of CD40L by glioma (Fig. 1), and that higher expression of CD40/
CD40L (by quantitative PCR) is a positive prognostic indicator of
survival. These data raise the issues of CD40/CD40L function in
cancer cells and whether there are some particularities in
glioma. Ligation of CD40 on tumor cells may have somewhat
different outcomes than normal immune cells, with proapop-
totic signaling reported for various lymphoid and solid tumors
as well as protumoral effects in low-grade B-cell malignancies.4
Furthermore, CD40/CD40L coexpression was a negative prog-
nostic factor in malignant melanoma.7 Concerning glioma,
CD40 ligation was reported to either induce secretion of
VEGF6 or induce no signaling at all.5 A major issue is that cell-
surface expression of CD40 may be insufficient for a biological
effect, as was observed for in vitro-cultured glioma lines.5 Ex-
pression in vivo can be difficult to assess, particularly if biopsies
are analyzed by reverse transcription-PCR or Western blot since
many nontumoral cells express both CD40 and CD40L. It is
noteworthy that glioma expression of CD40 was mainly cyto-
plasmic by immunohistochemistry,6 making any causative as-
sociation with prognosis difficult to justify. Regarding the novel
finding of CD40L expression in glioma and its positive correla-
tion with prognosis,1 it is conceivable that this could impact
tumor cell interactions with CD40-expressing immune cells in-
filtrating the tumor bed, but this remains to be determined.
In contrast to the speculative roles of CD40/CD40L ex-
pressed by glioma cells on disease progression, there is consid-
erable interest for therapeutically enhancing antitumor
immunity by administering CD40 ligands (antibodies or recom-
binant CD40L). Currently, 4 anti-CD40 antibodies are being ex-
plored clinically for certain cancer indications, with different
outcomes expected depending upon the epitope targeted,
the isotype, and whether the antibody is antagonistic or ago-
nistic.3,8 Moreover, CD40 ligation was previously validated in
the context of combination therapies in mouse models for gli-
oma.9,10 Chonan et al1 used an agonistic anti-CD40 antibody in
combination with a tumor lysate-based vaccine (in some cases
with dendritic cells) to treat mice bearing orthotopic GL261 gli-
omas or NSCL61 glioma-initiating cell (GIC)-like tumors (Fig. 1);
combination immunotherapy provided a major therapeutic
effect for GL261 but modest effect for the GIC tumor. For the
latter, addition immunostimulation with another immunosti-
mulatory antibody (against OX40) was required. It would be in-
teresting to know whether, in these models, sufficient
anti-CD40 antibody reached the tumor bed to ligate CD40 on
the glioma cells or on the pre-existing immune infiltrate, but
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this was not addressed. Both local effects (increased apoptosis,
reduced proliferation, and T cell infiltration) as well as systemic
effects (lymphocyte activation in the spleen) were observed,
but these effects would be compatible with the antibody inter-
acting with immune cells extracranially. One major mechanism
contributing to glioma progression is the balance and function
of myeloid cell populations.11,12 In this regard, agonistic
anti-CD40 antibodies can exert antitumor effects through my-
eloid cell activation or repolarization, as demonstrated clinically
in pancreatic carcinoma,13 and in combination with COX-2 inhi-
bition in mouse glioma models.9
Targeting CD40 for glioma therapy merits continued inves-
tigation, although arguably the issue of tumor cell expression
of CD40/CD40L is not a major concern for immunotherapy.
Since glioma, and glioblastoma in particular, is a poorly
immunogenic and highly immunosuppressive tumor, success-
ful immunotherapy will need us to “press the gas pedal”
(immunostimulation) as well as “release the brakes” (check-
point blockade).14 Clinical tools in the form of new generation
glioma vaccines and human or humanized agonistic and an-
tagonistic antibodies are now available for clinical trials. The
challenge now is to construct appropriate combinations and
to walk the tightrope of therapeutic potency and the inevita-
ble toxicities.
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